Clinical Trial Update: Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT [Phase 2]

View source ↗

Summary

Phase 2 trial of ibrutinib in patients with refractory/relapsed non-GCB diffuse large B-cell lymphoma who are non-candidates for autologous stem cell transplant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-10